Roche signs agreement to acquire mtm laboratories

October 30, 2017

mtm's second product, CINtec? Histology detects over-expression of p16 and is used in conjunction with traditional staining techniques to aid in the identification of high-grade cervical intraepithelial neoplasia (CIN) and cervical carcinoma in biopsy samples. This assay complements Roche's current market-leading menu of tissue-based cancer diagnostics.

"The combination of cobas HPV and p16 tests may redefine the standard of care for cervical cancer testing by improving detection, reducing unnecessary cervical biopsies, and improving the confirmation of cervical pre-cancer," added O'Day. "This comprehensive offering is unmatched in the diagnostics industry and will give Roche a superior competitive position in the field of cervical cancer testing."

"With its leadership position in the area of in vitro diagnostics and its global reach, Roche is the ideal company to accelerate adoption of next generation p16-based tests, which offer the promise to vastly improve the prevention of cervical cancer," commented Bob Silverman, CEO, mtm laboratories AG. "We're very excited about the future success of our products and pipeline as part of the Roche family."

SOURCE Ventana Medical Systems, Inc.